129 related articles for article (PubMed ID: 37257246)
1. OTUD1 chemosensitizes triple-negative breast cancer to doxorubicin by modulating P16 expression.
Zhou T; Wu Y; Qian D; Tang H; Liu X; Qiu J; Wang D; Hong W; Meng X; Zheng Q
Pathol Res Pract; 2023 Jul; 247():154571. PubMed ID: 37257246
[TBL] [Abstract][Full Text] [Related]
2. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
3. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
[TBL] [Abstract][Full Text] [Related]
4. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
Wu D; Jia H; Zhang Z; Li S
Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
[TBL] [Abstract][Full Text] [Related]
5. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
6. CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
Denard B; Jiang S; Peng Y; Ye J
BMC Cancer; 2018 Aug; 18(1):813. PubMed ID: 30103710
[TBL] [Abstract][Full Text] [Related]
7. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
8. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
9. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
10. PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer.
Zhuang F; Huang S; Liu L
Int J Biochem Cell Biol; 2024 Jun; 171():106581. PubMed ID: 38642827
[TBL] [Abstract][Full Text] [Related]
11. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract][Full Text] [Related]
12. Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6/MAPK signaling.
Huang S; Huang P; Wu H; Wang S; Liu G
Folia Histochem Cytobiol; 2021; 59(4):291-301. PubMed ID: 34970732
[TBL] [Abstract][Full Text] [Related]
13. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR.
Wang X; Chen T; Li C; Li W; Zhou X; Li Y; Luo D; Zhang N; Chen B; Wang L; Zhao W; Fu S; Yang Q
J Hematol Oncol; 2022 Aug; 15(1):122. PubMed ID: 36038948
[TBL] [Abstract][Full Text] [Related]
14. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication.
Sheng X; Dai H; Du Y; Peng J; Sha R; Yang F; Zhou L; Lin Y; Xu S; Wu Y; Yin W; Lu J
J Exp Clin Cancer Res; 2021 Jun; 40(1):205. PubMed ID: 34162418
[TBL] [Abstract][Full Text] [Related]
15. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
Wang S; Zhang J; Wang Y; Chen M
Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
[TBL] [Abstract][Full Text] [Related]
17. The deubiquitinase OTUD1 inhibits non-small cell lung cancer progression by deubiquitinating and stabilizing KLF4.
Ma X; Wang L; Shi G; Sun S
Thorac Cancer; 2022 Mar; 13(5):761-770. PubMed ID: 35098684
[TBL] [Abstract][Full Text] [Related]
18. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.
Bodenstine TM; Chandler GS; Reed DW; Margaryan NV; Gilgur A; Atkinson J; Ahmed N; Hyser M; Seftor EA; Strizzi L; Hendrix MJ
Cell Cycle; 2016 May; 15(9):1295-302. PubMed ID: 27007464
[TBL] [Abstract][Full Text] [Related]
19. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
20. OSW-1 induces apoptosis and cyto-protective autophagy, and synergizes with chemotherapy on triple negative breast cancer metastasis.
Wu M; Huang Q; Liao M; Wu X; Xi H; Ma H; Li S; Zhang Y; Xia Y
Cell Oncol (Dordr); 2022 Dec; 45(6):1255-1275. PubMed ID: 36155886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
